Anti-cancer drug valrubicin has the potential to be a good theranostic agent.
rHDL nanoparticles effectively shield hydrophobic valrubicin.
Use of rHDL nanoparticles can reduce toxicity and improve diagnostic time.
rHDl and free valrubicin have intrinsic fluorescence that can be used for imaging.
Compared to valrubicin, rHDL nanoparticles have longer lifetime and quantum yield.